Study Shows iCAD Solution Identifies Difficult to Detect Breast Cancers

Share Name	Share Symbol	Market	Type
Icade	EU:ICAD	Euronext	Ordinary Share

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-0.06	-0.21%	28.02	28.00	28.04	28.08	27.80	28.08	8,685	09:59:30

Icade (EU:ICAD)
Historical Stock Chart

From May 2019 to May 2024

Study Shows iCAD Solution Identifies Difficult to Detect Breast Cancers -- iCAD Second Look System Helps Generate Study Data -- NASHUA, N.H., March 29 /PRNewswire-FirstCall/ -- iCAD(R), Inc. (NASDAQ: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early detection of cancer, today announced that the Company's Second Look(R) system was used to generate data for "A Computer- Aided Detection System for the Evaluation of Breast Cancer by Mammographic Appearance and Lesion Size" study recently featured in the March 2005 edition of the American Journal of Roentgenology. Conducted by Dr. Rachel F. Brem, director of Breast Imaging at George Washington University in Washington DC, the study was devised to evaluate CAD performance in the detection of breast cancer based on appearance and size. Report findings conclude that CAD systems effectively help to detect breast cancers a radiologist may be more apt to initially miss. Small lesions are very challenging for the radiologist to detect, reported Dr. Brem, lead author of the study. The study of 201 women found that "CAD was highly effective in detecting even the smallest lesions, with a sensitivity of 92% for lesions of 5 mm or less." Findings also illustrate that CAD was most effective in detecting cancers measuring 11-15 mm (94%). They also reported that CAD can effectively detect "cancers smaller than or equal to 1 cm have a better prognosis than cancers greater than 1 cm," and therefore are important to detect. Subtle masses are also difficult to detect, Dr. Brem said. The study found that CAD had a sensitivity of 83% for the smallest masses (those measuring 1-5 mm). It was most sensitive for masses 11-15 mm (91%) and least sensitive for larger masses measuring greater than 20 mm (75%). This is because CAD is developed to detect smaller masses as cancers greater than 20 mm should be more readily detected by a radiologist. CAD systems assist the radiologist by "processing the breast films, using algorithms to detect suspicious areas and highlighting those areas," stated Dr. Brem. This study shows that CAD can help in the most difficult-to-detect cases. CAD prompts the radiologist to re-examine the films, and the radiologist decides whether "true areas of concern are present at the highlighted locations before making the final diagnosis," she continued. "When CAD is used as a prompt for the radiologist to identify potential areas of abnormality on the mammogram...it is a useful tool for the improved detection of breast cancer, regardless of the size of the cancer," Dr. Brem concludes. "As a strong proponent of medical research, iCAD was honored to take part in a study that proved how CAD positively impacts breast cancer prognosis," said Scott Parr, CEO at iCAD. "This study demonstrates the life-saving impact and potential our industry-leading CAD solutions offer." About iCAD, Inc. iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. Recipient of Frost & Sullivan's Growth Strategy Leadership award and repeatedly recognized as offering "The Winning Combination" of Price and Performance by MD Buyline, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 866 iCADnow or visit http://www.icadmed.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's other filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For more information on iCAD, Inc., contact Kevin McGrath of Cameron Associates at +1 212 245 4577 or via email at . DATASOURCE: iCAD, Inc. CONTACT: Kevin McGrath of Cameron Associates, +1-212-245-4577, Web site: http://www.icadmed.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ICAD Icade